| Active ingredients | Dosage form | Quantity of active ingredients | Shortage status | Availability | Reason | Last updated |
| nortriptyline | Tablet, film coated | 10 mg | Anticipated | Available | Manufacturing | 8/08/2025 |
| midazolam | Injection, solution | 15 mg | Current | Limited Availability | Manufacturing | 8/08/2025 |
| midazolam | Injection, solution | 50 mg | Current | Limited Availability | Manufacturing | 8/08/2025 |
| clopidogrel hydrogen sulfate | Tablet, film coated | 97.9 mg | Current | Limited Availability | Unexpected increase in consumer demand | 8/08/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | .125 mg | Current | Unavailable | Manufacturing | 8/08/2025 |
| levodopa~entacapone~carbidopa monohydrate | Tablet, film coated | 75 mg~200 mg~20.25 mg | Current | Limited Availability | Manufacturing | 8/08/2025 |
| quetiapine fumarate | Tablet, modified release | 460.52 mg | Resolved | Available | Manufacturing | 8/08/2025 |
| ivermectin | Cream | 10 mg/g | Resolved | Available | Manufacturing | 8/08/2025 |
| adrenaline (epinephrine) acid tartrate~articaine hydrochloride | Injection, solution | 18.2 microgram/mL~40 mg/mL | Anticipated | Available | Transport / Logistic issues / Storage capacity issues | 8/08/2025 |
| tobramycin | Eye Ointment | 3 mg/g | Anticipated | Available | Manufacturing | 8/08/2025 |
| phenytoin sodium | Capsule, hard | 30 mg | Anticipated | Available | Manufacturing | 8/08/2025 |
| nitrofurantoin | Capsule, hard | 100 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 8/08/2025 |
| bortezomib | Injection, solution | 3.5 mg | Current | Unavailable | Manufacturing | 8/08/2025 |
| hydralazine hydrochloride | Injection, powder for | 20 mg | Current | Unavailable | Manufacturing | 8/08/2025 |
| clopidogrel hydrogen sulfate | Tablet, film coated | 97.875 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 8/08/2025 |
| methylphenidate hydrochloride | Tablet, uncoated | 10 mg | Anticipated | Available | Manufacturing | 7/08/2025 |
| lamotrigine | Tablet, chewable | 200 mg | Anticipated | Available | Manufacturing | 7/08/2025 |
| metformin hydrochloride | Tablet, film coated | 500 mg | Current | Unavailable | Manufacturing | 7/08/2025 |
| Pancreatic extract | Capsule, enteric | 300 mg | Anticipated | Available | Unexpected increase in consumer demand | 7/08/2025 |
| methylphenidate hydrochloride | Capsule, modified release | 10 mg | Current | Limited Availability | Manufacturing | 7/08/2025 |
| Choriogonadotropin alfa | Injection, solution | 250 microgram | Current | Limited Availability | Unexpected increase in consumer demand | 7/08/2025 |
| indapamide hemihydrate | Tablet, sugar coated | 2.5 mg | Anticipated | Available | Manufacturing | 7/08/2025 |
| metformin hydrochloride | Tablet, film coated | 1000 mg | Current | Unavailable | Manufacturing | 7/08/2025 |
| oxytocin | Injection, solution | 5 IU/mL | Current | Limited Availability | Unexpected increase in consumer demand | 7/08/2025 |
| capecitabine | Tablet, film coated | 500 mg | Current | Limited Availability | Unexpected increase in consumer demand | 7/08/2025 |
| lansoprazole | Tablet, orally disintegrating | 15 mg | Anticipated | Available | Manufacturing | 7/08/2025 |
| pramipexole dihydrochloride monohydrate | Tablet, modified release | .75 mg | Anticipated | Available | Manufacturing | 7/08/2025 |
| pramipexole dihydrochloride monohydrate | Tablet, modified release | 1.5 mg | Anticipated | Available | Manufacturing | 7/08/2025 |
| pramipexole dihydrochloride monohydrate | Tablet, modified release | 2.25 mg | Current | Limited Availability | Manufacturing | 7/08/2025 |
| methylphenidate hydrochloride | Capsule, modified release | 60 mg | Current | Limited Availability | Manufacturing | 7/08/2025 |
| atomoxetine hydrochloride | Capsule, hard | 45.72 mg | Current | Unavailable | Manufacturing | 7/08/2025 |
| metformin hydrochloride | Tablet, film coated | 1000 mg | Current | Unavailable | Unexpected increase in consumer demand | 7/08/2025 |
| lacosamide | Tablet, film coated | 50 mg | Anticipated | Available | Manufacturing | 7/08/2025 |
| Pancreatic extract | Capsule | 420 mg | Anticipated | Available | Unexpected increase in consumer demand | 7/08/2025 |
| midazolam maleate | Solution | 10.2 mg | Current | Limited Availability | Manufacturing | 7/08/2025 |
| lanreotide acetate | Injection, solution | 133.33 mg | Current | Unavailable | Manufacturing | 7/08/2025 |
| levothyroxine sodium | Tablet | 100 microgram | Current | Unavailable | Unexpected increase in consumer demand | 7/08/2025 |
| Teriparatide | Injection, solution | 250 microgram/mL | Anticipated | Available | Manufacturing | 7/08/2025 |
| methylphenidate hydrochloride | Capsule, modified release | 20 mg | Current | Limited Availability | Manufacturing | 7/08/2025 |
| methylphenidate hydrochloride | Capsule, modified release | 40 mg | Current | Limited Availability | Manufacturing | 7/08/2025 |
| flecainide acetate | Injection, solution | 10 mg/mL | Current | Unavailable | Manufacturing | 6/08/2025 |
| metformin hydrochloride | Tablet, film coated | 850 mg | Current | Unavailable | Manufacturing | 6/08/2025 |
| brimonidine tartrate | Eye Drops, solution | 1.5 mg/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 6/08/2025 |
| letrozole | Tablet, film coated | 2.5 mg | Current | Limited Availability | Manufacturing | 6/08/2025 |
| phenobarbital sodium | Injection, solution | 219 mg/mL | Resolved | Available | Manufacturing | 6/08/2025 |
| sumatriptan succinate | Tablet, film coated | 139.98 mg | Resolved | Available | Manufacturing | 6/08/2025 |
| lansoprazole | Tablet, orally disintegrating | 30 mg | Current | Limited Availability | Manufacturing | 6/08/2025 |
| hydromorphone hydrochloride | Injection, solution | 2 mg/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 6/08/2025 |
| cinacalcet hydrochloride | Tablet, film coated | 99 mg | Resolved | Available | Manufacturing | 6/08/2025 |
| lurasidone hydrochloride | Tablet, film coated | 80 mg | Current | Unavailable | Manufacturing | 6/08/2025 |
| methylphenidate hydrochloride | Capsule, hard | 40 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 6/08/2025 |
| methylphenidate hydrochloride | Capsule, hard | 10 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 6/08/2025 |
| methylphenidate hydrochloride | Capsule, hard | 60 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 6/08/2025 |
| sirolimus | Oral Liquid, solution | 1 mg/mL | Current | Limited Availability | Manufacturing | 6/08/2025 |
| lorazepam | Tablet, uncoated | 1 mg | Resolved | Available | Manufacturing | 5/08/2025 |
| phenoxymethylpenicillin potassium | Oral Liquid, powder for | 28.284 mg/mL | Anticipated | Available | Manufacturing | 5/08/2025 |
| olanzapine | Tablet, orally disintegrating | 5 mg | Resolved | Available | Manufacturing | 5/08/2025 |
| amoxicillin trihydrate | Capsule, hard | 286.95 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 5/08/2025 |
| encorafenib | Capsule, hard | 50 mg | Current | Unavailable | Manufacturing | 5/08/2025 |
| daptomycin | Injection, powder for | 350 mg | Current | Limited Availability | Manufacturing | 5/08/2025 |
| montelukast sodium | Tablet, chewable | 5.2 mg | Current | Unavailable | Manufacturing | 5/08/2025 |
| deferasirox | Tablet, film coated | 360 mg | Current | Limited Availability | Manufacturing | 5/08/2025 |
| methylphenidate hydrochloride | Capsule, hard | 30 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 5/08/2025 |
| levothyroxine sodium | Tablet | 200 microgram | Current | Unavailable | Unexpected increase in consumer demand | 5/08/2025 |
| melatonin | Capsule, hard | 2 mg | Current | Unavailable | Unexpected increase in consumer demand | 5/08/2025 |
| mirtazapine | Tablet, film coated | 30 mg | Current | Limited Availability | Manufacturing | 5/08/2025 |
| propofol | Injection, emulsion | 200 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 4/08/2025 |
| phenoxymethylpenicillin potassium | Tablet, film coated | 560 mg | Anticipated | Available | Manufacturing | 4/08/2025 |
| atorvastatin calcium trihydrate~ezetimibe | Tablet, film coated | 82.725 mg~10 mg | Resolved | Available | Manufacturing | 4/08/2025 |
| naloxone hydrochloride dihydrate | Injection | 440 microgram | Current | Unavailable | Unexpected increase in consumer demand | 4/08/2025 |
| levothyroxine sodium | Tablet, uncoated | .1 mg | Resolved | Available | Manufacturing | 4/08/2025 |
| enoxaparin sodium | Injection, solution | 60 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 4/08/2025 |
| flecainide acetate | Tablet, uncoated | 100 mg | Resolved | Available | Manufacturing | 4/08/2025 |
| metformin hydrochloride | Tablet, film coated | 850 mg | Resolved | Available | Manufacturing | 4/08/2025 |
| pioglitazone hydrochloride | Tablet, uncoated | 49.59 mg | Current | Unavailable | Commercial Changes / Commercial viability | 4/08/2025 |
2025年8月11日